The JAMA Network Open article of 01/26/2026 titled “Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs”
is revelatory–
🧠Study Overview
- Topic and link: Mobile telemedicine for treating chronic hepatitis C (HCV)
- Population: 150 rural adults who inject drugs (high-risk group for HCV)
- Design: Randomized clinical trial comparing:
- Mobile telemedicine care (MTC) via a van
- Enhanced usual care (EUC) (referral + care navigation)
🔑 Key Findings
- Treatment initiation:
- 57% (telemedicine) vs 27% (usual care)
- Viral cure (clearance):
- 37% vs 19%
- → Telemedicine roughly doubled both treatment uptake and cure rates
- Risk behaviors (needle sharing):
- No significant difference between groups
💡 What Made the Intervention Different
- Care delivered directly to patients via a mobile van
- Integrated with syringe services (harm reduction)
- Included on-site telemedicine prescribing of antiviral therapy
📊 Why It Matters
- Rural populations have:
- High HCV prevalence
- Poor access to specialty care
- This study shows that bringing telemedicine to patients (vs referring them) dramatically improves outcomes
- Supports telemedicine as a key strategy for HCV elimination, especially in underserved areas
🧠Bottom Line
Mobile, low-barrier telemedicine significantly improves access to and success of hepatitis C treatment in high-risk rural populations—but does not change risky injection behaviors on its own.